N-phenylacridin-9-amine derivative having anticancer activity on the human nasopharyngeal carcinoma (HONE-1)\r\ncell line, human adenocarcinoma (colon and rectal) tumor (HT-29) cell line, human brain tumor (DBTRG) cell line, gastric\r\ncarcinoma TSGH, hepatoma liver Hepa-G2, mouth carcinoma KB, lung adenocarcinoma H460, breast adenocarcinoma MX-1 and\r\nMCF-7 cell line and it�s significant cytotoxic activity against human leukemic HL-60 cell growth. N-phenylacridin-9-amine\r\nderivative exhibit both in-vivo as well as in-vitro potent antitumor activity. The alkylcarbamates of the N-phenylacridin-9-amine\r\nis more effective than their corresponding parent N-phenylacridin-9-amine derivatives. The cytotoxic activity of the Nphenylacridin-\r\n9-amine ethylcarbamates is decreased with increasing length and size of the alkyl function. It is also having drug-\r\nDNA binding affinity which affects the antitumor activity of 9-anilinoacridines. These compound having higher cytotoxic activity\r\ndue to high lipophilicity. We have used 25 compounds and those pIC50 activities on the HONE-1 cell line for the 2-D QSAR study.\r\nHere the 2D-QSAR studies of N-phenylacridin-9-amine analogues were performed by using software chem-draw ultra-8.0,\r\nopenbable-2.2.1, dragon, valstat. We are considering here two model equations for QSAR study. The value of linearity r2 for\r\nmodel-1 of HONE-1 cell line (model-1) is; r2 = 0.88699, Q2 = 0.800012, Spress = 0.3513 and SDEP = 0.321972 while this value for\r\nmodel-2 of HONE-1 cell line is; r2 = 0.879216, Q2 = 0.784529, Spress = 0.364646 and SDEP = 0.334203. Both models were\r\nvalidated by the Valstat software.
Loading....